🇺🇸 FDA
Pipeline program

ISIS EIF4E Rx

ISIS 183750-CS4

Phase 2 small_molecule completed

Quick answer

ISIS EIF4E Rx for Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
IONIS PHARMACEUTICALS INC
Indication
Non-small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials